Table 2 Clinical findings and treatment outcomes in eight cases of WD with osseomuscular type
From: Clinical features and outcome in patients with osseomuscular type of Wilson’s disease
No | K-F ring | Neurologic Examination | CP (g/L) | Involvement on brain MRI | Abdominal ultrasonography | Outcomes of Chelation Therapy (Degreea) | ||
|---|---|---|---|---|---|---|---|---|
Strength | Tone | Reflex | ||||||
1 | + | UE & LE 5 | UE ↑ | (++) | <0.02 | Basal ganglia | Hepatic diffuse disease | (9 months after treatment) Dystonia in the right hand partially relieved; blurred speech persist; walking better (2) |
2 | + | UE & LE 5 | Normal | (++) | 0.02 | Basal ganglia and brain stem | Hepatic diffuse disease, splenomegaly | (3 months after the treatment) Pain relieved with improved speech (0) |
3 | + | UE & LE 5 | Normal | (++) | <0.02 | Normal | Hepatic diffuse disease, splenomegaly | (14 months after treatment) Pain relieved (0) |
4 | + | UE & LE 5 | UE & LE ↑ | (++) | 0.07 | N/A | Hepatic diffuse disease | (after 23 months of inconsecutive treatment) No obvious improvement (3) |
5 | N/A | UE & LE 5 | UE ↑ | UE & LE (+++) | 0.03 | Basal ganglia and brain stem | Hepatic diffuse disease, splenomegaly | N/A |
6 | + | UE & LE 5 | UE & LE ↓ | (++) | 0.03 | N/A | Normal | N/A |
7 | + | UE 5; pLE 4; dLE 4- | UE & LE ↓ | Knee (+++) | 0.02 | N/A | Hepatic diffuse disease, splenomegaly | N/A |
8 | - | UE 4; LE 4- | LE ↑ | Knee (+++) | 0.05 | Normal | Increased echogenicity | (6 months after treatment) Pain relieved with improved joint motion (2) |